


FIG. 1. From Clinical Pharmacokinetics, 26(14):41-66




FIG. 2. Simulated viral dynamic profiles of 4 weeks of lamivudine treatment at 5-600 mg/day




FIG. 3. Lamivudine dose optimization by Emax modeling




FIG.4. Time course of serum HBV DNA in patient TMS following treatment initiation with *de novo* combination of lamivudine 600mg/day and adefovir dipivoxil 5mg/day




FIG.5. Time course of serum ALT in patient TMS following treatment initiation with *de novo* combination of lamivudine 600mg/day and adefovir dipivoxil 5mg/daym (ULN: upper limit of normal)